A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

[1]  M. Gleave,et al.  The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors , 2015, International journal of cancer.

[2]  S. Conzen,et al.  Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[3]  M. Yunokawa,et al.  Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer , 2012, Cancer Chemotherapy and Pharmacology.

[4]  S. Conzen,et al.  Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. , 2011, Cancer research.

[5]  V. Roy,et al.  Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer , 2011, Breast cancer : basic and clinical research.

[6]  O. Olopade,et al.  Glucocorticoid receptor expression in breast cancer associates with older patient age , 2009, Breast Cancer Research and Treatment.

[7]  S. Conzen.  Minireview: nuclear receptors and breast cancer. , 2008, Molecular endocrinology.

[8]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Robert,et al.  Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. , 2007, Clinical breast cancer.

[10]  B. Allolio,et al.  Mifepristone (RU 486) in Cushing's syndrome. , 2007, European journal of endocrinology.

[11]  Neil Desai,et al.  Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Wei Wu,et al.  Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial Cells , 2004, Cancer Research.

[13]  G. Shepherd.  Hypersensitivity reactions to chemotherapeutic drugs , 2003, Clinical reviews in allergy & immunology.

[14]  J. Foekens,et al.  Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer , 2000, Steroids.

[15]  E. Eisenhauer,et al.  Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Kato,et al.  Inhibition by dexamethasone of human neutrophil apoptosis in vitro. , 1995, Natural immunity.

[17]  C. Bardin,et al.  Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. , 1993, The New England journal of medicine.

[18]  J. Foekens,et al.  Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  G. Romieu,et al.  The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. , 1986, Bulletin du cancer.

[20]  G. Chrousos,et al.  Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. , 1985, The Journal of clinical endocrinology and metabolism.

[21]  E. Gelmann,et al.  Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. , 2004, Molecular endocrinology.